vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $153.1M, roughly 1.2× CPI Card Group Inc.). CPI Card Group Inc. runs the higher net margin — 4.8% vs -0.7%, a 5.5% gap on every dollar of revenue. On growth, CPI Card Group Inc. posted the faster year-over-year revenue change (22.3% vs 0.7%). CPI Card Group Inc. produced more free cash flow last quarter ($35.2M vs $21.3M). Over the past eight quarters, CPI Card Group Inc.'s revenue compounded faster (16.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.
AVNS vs PMTS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $153.1M |
| Net Profit | $-1.3M | $7.3M |
| Gross Margin | 47.5% | 31.5% |
| Operating Margin | 1.4% | 12.0% |
| Net Margin | -0.7% | 4.8% |
| Revenue YoY | 0.7% | 22.3% |
| Net Profit YoY | 99.7% | 8.5% |
| EPS (diluted) | $-0.02 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $153.1M | ||
| Q3 25 | $177.8M | $138.0M | ||
| Q2 25 | $175.0M | $129.8M | ||
| Q1 25 | $167.5M | $122.8M | ||
| Q4 24 | $179.6M | $125.1M | ||
| Q3 24 | $170.4M | $124.8M | ||
| Q2 24 | $171.7M | $118.8M | ||
| Q1 24 | $166.1M | $111.9M |
| Q4 25 | $-1.3M | $7.3M | ||
| Q3 25 | $-1.4M | $2.3M | ||
| Q2 25 | $-76.8M | $518.0K | ||
| Q1 25 | $6.6M | $4.8M | ||
| Q4 24 | $-397.3M | $6.8M | ||
| Q3 24 | $4.3M | $1.3M | ||
| Q2 24 | $1.8M | $6.0M | ||
| Q1 24 | $-900.0K | $5.5M |
| Q4 25 | 47.5% | 31.5% | ||
| Q3 25 | 48.4% | 29.7% | ||
| Q2 25 | 52.6% | 30.9% | ||
| Q1 25 | 53.6% | 33.2% | ||
| Q4 24 | 54.6% | 34.1% | ||
| Q3 24 | 54.5% | 35.8% | ||
| Q2 24 | 55.7% | 35.7% | ||
| Q1 24 | 57.1% | 37.1% |
| Q4 25 | 1.4% | 12.0% | ||
| Q3 25 | 0.1% | 9.4% | ||
| Q2 25 | -42.6% | 7.3% | ||
| Q1 25 | 6.1% | 11.5% | ||
| Q4 24 | -233.0% | 12.7% | ||
| Q3 24 | 7.0% | 14.3% | ||
| Q2 24 | 3.7% | 12.5% | ||
| Q1 24 | 2.4% | 12.6% |
| Q4 25 | -0.7% | 4.8% | ||
| Q3 25 | -0.8% | 1.7% | ||
| Q2 25 | -43.9% | 0.4% | ||
| Q1 25 | 3.9% | 3.9% | ||
| Q4 24 | -221.2% | 5.4% | ||
| Q3 24 | 2.5% | 1.0% | ||
| Q2 24 | 1.0% | 5.1% | ||
| Q1 24 | -0.5% | 4.9% |
| Q4 25 | $-0.02 | $0.62 | ||
| Q3 25 | $-0.03 | $0.19 | ||
| Q2 25 | $-1.66 | $0.04 | ||
| Q1 25 | $0.14 | $0.40 | ||
| Q4 24 | $-8.64 | $0.56 | ||
| Q3 24 | $0.09 | $0.11 | ||
| Q2 24 | $0.04 | $0.51 | ||
| Q1 24 | $-0.02 | $0.46 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $21.7M |
| Total DebtLower is stronger | $90.3M | $286.7M |
| Stockholders' EquityBook value | $778.2M | $-17.3M |
| Total Assets | $1.1B | $403.2M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $21.7M | ||
| Q3 25 | $70.5M | $16.0M | ||
| Q2 25 | $90.3M | $17.1M | ||
| Q1 25 | $97.0M | $31.5M | ||
| Q4 24 | $107.7M | $33.5M | ||
| Q3 24 | $89.0M | $14.7M | ||
| Q2 24 | $92.2M | $7.5M | ||
| Q1 24 | $75.8M | $17.1M |
| Q4 25 | $90.3M | $286.7M | ||
| Q3 25 | $93.4M | $308.4M | ||
| Q2 25 | $95.7M | $310.9M | ||
| Q1 25 | $98.0M | $280.7M | ||
| Q4 24 | $125.3M | $280.4M | ||
| Q3 24 | $152.6M | $280.2M | ||
| Q2 24 | $164.9M | $269.7M | ||
| Q1 24 | $167.2M | $265.3M |
| Q4 25 | $778.2M | $-17.3M | ||
| Q3 25 | $778.0M | $-25.7M | ||
| Q2 25 | $776.3M | $-29.0M | ||
| Q1 25 | $839.4M | $-29.7M | ||
| Q4 24 | $828.5M | $-35.6M | ||
| Q3 24 | $1.2B | $-42.8M | ||
| Q2 24 | $1.2B | $-44.6M | ||
| Q1 24 | $1.2B | $-48.5M |
| Q4 25 | $1.1B | $403.2M | ||
| Q3 25 | $1.1B | $407.1M | ||
| Q2 25 | $1.0B | $399.8M | ||
| Q1 25 | $1.1B | $351.9M | ||
| Q4 24 | $1.2B | $349.7M | ||
| Q3 24 | $1.7B | $342.3M | ||
| Q2 24 | $1.7B | $321.4M | ||
| Q1 24 | $1.7B | $319.8M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $39.6M |
| Free Cash FlowOCF − Capex | $21.3M | $35.2M |
| FCF MarginFCF / Revenue | 11.8% | 23.0% |
| Capex IntensityCapex / Revenue | 3.8% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 5.39× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $41.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $39.6M | ||
| Q3 25 | $14.0M | $10.0M | ||
| Q2 25 | $6.8M | $4.3M | ||
| Q1 25 | $25.7M | $5.6M | ||
| Q4 24 | $57.9M | $26.7M | ||
| Q3 24 | $23.0M | $12.5M | ||
| Q2 24 | $27.8M | $-4.8M | ||
| Q1 24 | $-8.0M | $8.9M |
| Q4 25 | $21.3M | $35.2M | ||
| Q3 25 | $7.0M | $5.3M | ||
| Q2 25 | $-4.2M | $533.0K | ||
| Q1 25 | $19.0M | $292.0K | ||
| Q4 24 | $53.1M | $21.6M | ||
| Q3 24 | $20.0M | $11.1M | ||
| Q2 24 | $21.9M | $-6.0M | ||
| Q1 24 | $-12.1M | $7.4M |
| Q4 25 | 11.8% | 23.0% | ||
| Q3 25 | 3.9% | 3.8% | ||
| Q2 25 | -2.4% | 0.4% | ||
| Q1 25 | 11.3% | 0.2% | ||
| Q4 24 | 29.6% | 17.3% | ||
| Q3 24 | 11.7% | 8.9% | ||
| Q2 24 | 12.8% | -5.0% | ||
| Q1 24 | -7.3% | 6.6% |
| Q4 25 | 3.8% | 2.9% | ||
| Q3 25 | 3.9% | 3.4% | ||
| Q2 25 | 6.3% | 2.9% | ||
| Q1 25 | 4.0% | 4.3% | ||
| Q4 24 | 2.7% | 4.0% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 3.4% | 1.0% | ||
| Q1 24 | 2.5% | 1.3% |
| Q4 25 | — | 5.39× | ||
| Q3 25 | — | 4.32× | ||
| Q2 25 | — | 8.39× | ||
| Q1 25 | 3.89× | 1.17× | ||
| Q4 24 | — | 3.94× | ||
| Q3 24 | 5.35× | 9.70× | ||
| Q2 24 | 15.44× | -0.79× | ||
| Q1 24 | — | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PMTS
| US Debit And Credit | $128.9M | 84% |
| US Prepaid Debit | $24.4M | 16% |
